



## “Gene Therapy in the Eye” – Basics and recent developments in its success

Anshuman Verma<sup>1</sup> Lalan Kumar Arya<sup>2</sup> Sushil Dubey<sup>3</sup>

1. MNR Foundation for Research and Innovation, MNR Medical College, Sangareddy, Hyderabad, Telangana, India.
2. Regional Institute of Ophthalmology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India.
3. East Tennessee State University, Johnson City, Tennessee, USA.

**Corresponding author:** Dr. Anshuman Verma, Scientist

**Email –** [drverma.fri@mnrindia.org](mailto:drverma.fri@mnrindia.org)

### Key

### words:

LCA,  
Gene  
Therapy,  
Congenital  
Blindness

### Abstract:

Ever since the genetic basis of phenotypic variance and disease occurrence was discovered, scientists and clinicians have hoped that “correcting” mutations may be the panacea for many human ailments. Over the past several years, Gene therapy [GT] has evolved from an idea to a reality, with over 1800 clinical trials being piloted worldwide. The target ailments vary from cancer to inherited diseases to complex disorders. A variety of GT modalities have emerged, which typically range in their delivery methods to the target tissues. Both viral and non-viral methods of gene delivery are getting advanced, but viral vectors have gained greater attention due to their superior gene delivery efficiencies. The GT process has been particularly successful in the eye and holds great promise for curing various forms of blinding disorders. This review will discuss the basics of GT process, prospect of ocular GT, and its recent developments.